Gilead Sciences: executives sold shares under predetermined plans
On October 15, 2026, two Gilead Sciences executives, Chief Financial Officer Andrew Dickinson and Chief Communications Officer Johanna Mercier, sold company shares. Each sold 3,000 shares at $156.22 per share, totaling approximately $468,660 for each transaction. Both operations were conducted under pre-approved trading plans, which set a specific sale schedule.
Key points
- Chief Financial Officer Andrew Dickinson sold 3,000 shares on October 15, 2026.
- On the same day, October 15, 2026, Chief Communications and Corporate Affairs Officer Johanna Mercier also sold 3,000 shares of Gilead Sciences.
- After the specified transactions, 161,096 shares remain in Andrew Dickinson's balance.
Chief financial officer share sale
Chief Financial Officer Andrew Dickinson sold 3,000 shares on October 15, 2026. The average sale price was $156.22 per share, and the total transaction value reached $468,660. The sale took place in accordance with a trading plan adopted on August 29, 2024, as verified in company documents.
Volume of share sales by Gilead Sciences executives
Operations by chief communications officer
On the same day, October 15, 2026, Chief Communications and Corporate Affairs Officer Johanna Mercier also sold 3,000 shares of Gilead Sciences. The sale price was the same—$156.22 per share—and the total value of the transaction was $468,660. This operation was executed under a plan adopted on February 20, 2025.
Insider actions and share ownership
After the specified transactions, 161,096 shares remain in Andrew Dickinson's balance. After the sale, Johanna Mercier holds 113,684 shares. Both executives used pre-approved trading plans to sell their assets.
Next steps
Shareholders can track further executive transactions through transaction reports that the company submits to regulatory bodies after any significant change in insider ownership. These reports are published on official market regulator resources.
Original sources
- 144 filing, October 15, 2026
- 144 filing, October 15, 2026
- 4 filing, October 16, 2026
- 4 filing, October 16, 2026
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Gilead Sciences
A notification in your browser or on your phone when we publish about Gilead Sciences. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
